Who Paid My Doc
Ari Isaacson
Vascular & Interventional Radiology Chapel Hill, NC Medical Doctor
NPI 1982674586 CMS profile 818095
101 Manning Dr, Chapel Hill, NC 27514
General payments
$290,241
Research payments
$87,424
Ownership & investment interest
$0
Research they led as principal investigator
$54,299
Through program year 2025, Ari Isaacson of Chapel Hill, NC is reported in the CMS Open Payments database as having received $290,241 across 313 general payments and $87,424 in research payments paid to them. Separately, studies naming them as principal investigator received $54,299 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $62,924 | 64 | |
| 2024 | General | $54,420 | 57 | |
| 2023 | General | $42,725 | 48 | |
| 2022 | General | $34,426 | 31 | |
| 2021 | General | $28,135 | 26 | |
| 2020 | General | $39,559 | 32 | |
| 2019 | General | $28,053 | 55 | |
| 2019 | Research | $87,424 | 2 |
Beside peers
- Ari Isaacson
- Vascular & Interventional Radiology median
- Middle half of Vascular & Interventional Radiology
- National median
In program year 2025, general payments to Ari Isaacson were reported at $62,924. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.
Show as a table
| Year | Ari Isaacson | Vascular & Interventional Radiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $28,053 | $422 | $125–$1,555 | $163 |
| 2020 | $39,559 | $200 | $68–$652 | $114 |
| 2021 | $28,135 | $280 | $99–$866 | $132 |
| 2022 | $34,426 | $433 | $137–$1,497 | $149 |
| 2023 | $42,725 | $506 | $152–$2,019 | $160 |
| 2024 | $54,420 | $556 | $175–$1,930 | $164 |
| 2025 | $62,924 | $534 | $166–$2,075 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
2,109
Drug cost
$7,627
Branded share of claims
25.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Methylprednisolone | Generic | 566 | $3,094 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 280 | $2,093 | |
| Naproxen | Generic | 384 | $735 | |
| Famotidine | Generic | 498 | $652 | |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | Brand | 253 | $528 | |
| Phenazopyridine Hcl | Generic | 98 | $405 | |
| Ciprofloxacin Hcl | Generic | 30 | $119 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 41 billing codesPaid by Medicare
$2,255,948
Medicare patients
387
Services billed
15,173
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 40% | |
| Ischemic heart disease | 35% | |
| Diabetes | 30% | |
| Atrial fibrillation | 25% | |
| Chronic kidney disease | 25% | |
| Cancer | 16% | |
| Heart failure | 14% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 202 | 11,236 | $1,136 |
| Injection, methylprednisolone sodium succinate, up to 125 mg J2930 | Office | 65 | 67 | $300 |
| Injection, cefazolin sodium, 500 mg J0690 | Office | 198 | 423 | $261 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
315 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Vascular & Interventional Radiology in North Carolina
Gloria Salazar
Vascular & Interventional Radiology · Chapel Hill, NC
Brian Kouri
Vascular & Interventional Radiology · Winston Salem, NC
Nicole Keefe
Vascular & Interventional Radiology · Chapel Hill, NC
William Pechter
Vascular & Interventional Radiology · Cary, NC
Stephen Loehr
Vascular & Interventional Radiology · Cary, NC
Jeremy Kim
Vascular & Interventional Radiology · Charlotte, NC
Related records
Vascular & Interventional Radiology in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Vascular & Interventional Radiology
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.